Nurix reports FY2025 net loss of $264.5M; initiates DAYBreak registrational program for bexobrutideg

Nurix Therapeutics, Inc.

2025-FY EPS reported -$3.05 revenue$83,980,000

FY2025 revenue $84.0M (+54% YoY); net loss $264.5M ($3.05/sh) vs $193.6M ($2.88/sh) last year.
Bexobrutideg Phase 1 in r/r CLL: 83% ORR, median PFS 22.1 months; DAYBreak pivotal Phase 2 initiated at 600 mg.
Completed $250M stock offering in Oct 2025; cash, cash equivalents & marketable securities $592.9M.
Appointed Roger Dansey to Board; Phase 3 randomized trial vs pirtobrutinib expected H1 2026.
Preclinical IRAK4 degrader GS-6791 data presented; Phase 1 HV study ongoing; autoimmune IND planned 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.